QUCY Overview

Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.

Wall Street analysts forecast QUCY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for QUCY is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Mainz Biomed NV revenue for the last quarter amounts to NaN USD, decreased

Mainz Biomed NV. EPS for the last quarter amounts to USD, decreased

Mainz Biomed NV (QUCY) has 19 emplpoyees as of March 30 2026.

Today QUCY has the market capitalization of 5.51M USD.